October 30, 2012 ·
Leave a comment
Thought Leader Select is a company focused on driving industry collaborations among biopharmaceutical, medical device, and diagnostics companies with leading medical experts and centers of excellence, with the ultimate goals of these collaborations being two-fold in purpose: better treatment options for patients and better outcomes for global public health. As part of our company’s mission, we work with multiple organizations to promote best practices that deliver ethical, transparent interactions among these various healthcare constituencies.
One of these groups is the recently-launched Medical Science Liaison Society, a global Non-Profit organization being led by the Chairman of the Board, Dr. Samuel Dyer. The MSL Society is filling a vital need for the expanding role of Medical Science Liaisons around the world, as they collaborate with KOLs, physicians, and other health care professionals to advance medical science together to improve the quality of life for patients everywhere.
Thought Leader Select’s Allison Murphy, a veteran MSL herself from her days working in the Endocrinology Medical Affairs unit at Eli Lilly and Company, recently sat down with Dr. Dyer to learn more about this emerging organization and the impact the MSL Society is having in promoting the role of Medical Science Liaisons in the pharmaceutical, biopharmaceutical, medical device, and diagnostics industries.
In ... read more »
April 12, 2012 ·
Leave a comment
New press release out today from the offices of Thought Leader Select:
April 12, 2012 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based consulting firm supporting the healthcare industry, is pleased to announce the hiring of Jason Bell as its newest sales executive for the American market.
Bell comes to Thought Leader Select with a solid track record of experience within the biopharmaceutical industry, working as a field hospital representative in support of critical new drug launches in multiple therapeutic areas and disease states, for companies including Allergan, Capellon Pharmaceuticals, and Auriga Pharmaceuticals. In addition to his in-the-field experience and perspective on collaborating with key opinion leaders in medicine to promote effective new treatments, Bell also brings experience gleaned from his time at Clinsys Alterna, a contract research organization (CRO). In his business development role at Clinsys Alterna, Jason consulted with biopharmaceutical industry executives to deliver customized solutions in support of phase I-IV clinical trials.
Jason Bell is a 1997 graduate of California University of Pennsylvania, with a degree in psychology.
“I’m already enjoying my work, speaking with clients and prospective clients about their needs for medical marketing and medical science outreach to health care professionals,” stated Bell. “This company is a great match for my experience and the skills I developed in pharma, CROs, and talent management organizations serving life science ... read more »
June 24, 2010 ·
Leave a comment
Industry Insights from Paul Meade, M. Sc, MPH
A recent report suggested that patients can have a significant influence on the success or failure of new drugs. The “New Health Report,” conducted by Richard Day Research and published by Quintiles, a large multinational contract research organization (CRO) to the pharmaceutical industry, surveyed executives from biopharmaceutical companies and from healthcare companies, as well as a number of patients. They found that patients are gradually moving into a position of influence over the success of a new medicine, a position long held by the medical community.
There is an old saying in the art of negotiating– “whoever believes he has the power, has the power.” This interesting paradox can be seen in government. The politicians believe they have the power, and so they wield it readily to control the people; whereas the people do not believe they have the power, and are thus subjugated to the will of the government. In reality, it is the opposite. The government derives its power from the people, and the people of the land have the real power. But in most cases, the government believes it has the power, as so it does.
In medicine, physicians have always held a position of power over the interventions of diseases. They make life and death decisions armed with a wealth of ... read more »
February 25, 2010 ·
Leave a comment
According to a February 2010 article in Outsourcing-Pharma.com, pharmaceutical companies will continue to outsource more of their business to single-service providers. To capture more business, CROs will merge or focus on niche opportunities.
Thought Leader Select, a research firm providing sophisticated KOL deployment strategies to the pharma and biotech industries, has developed a unique opportunity to provide pharma companies – through their outsourced partnerships with CROs and other research outfits – predictive models for selecting clinical investigators. These models, known as Clinical Investigator Success Plans, match the skills, experiences, and preferences of clinical investigators with companies’ trial protocols to improve the success rates of their studies.
Companies can often trace clinical trial pitfalls to their investigators’ abilities to recruit the right patients in a timely fashion, according to Paul Meade, President of Thought Leader Select. “When companies understand the trial environments that best match the clinical investigator’s strengths, they will ultimately avoid setbacks that delay trials from meeting critical endpoints and also avoid over-spending on clinical research,” said Meade, a 25-year veteran of the pharmaceutical industry.
Read the full Outsourcing-Pharma.com article here.
read more »